Paxmedica, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink

14 Jan 2026

PXMD

10-Q: Kuvatris Therapeutics Navigates Delisting, Going Private

Kuvatris Therapeutics, formerly PaxMedica, Inc., filed its Q3 2024 10-Q to comply with FINRA, revealing a going-private transaction, significant financial losses, and ongoing liquidity challenges.

OTC.Pink

20 Sept 2024

PXMD

Paxmedica, INC

10-Q: PaxMedica Reports Q2 2024 Results, Faces Going Concern Uncertainty Amidst Nasdaq Suspension

PaxMedica's Q2 2024 report reveals ongoing losses and a cash balance of $0.3 million, alongside a suspension from the Nasdaq Capital Market, raising concerns about the company's ability to continue as a going concern.

OTC.Pink

13 May 2024

PXMD

Paxmedica, INC

10-Q: PaxMedica Reports Q1 2024 Results, Cites Ongoing Losses and Delisting from Nasdaq

PaxMedica reported a net loss of $3.7 million for the first quarter of 2024 and disclosed its delisting from the Nasdaq Capital Market.